Pharmaceutical Excipients Global Market - Forecast to 2029

Publishing Date : February, 2023
Report Code : HCPH 0102
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Pharmaceutical excipients are inactive substances in the drug which help in modulating the solubility, bioavailability, and stability of active substances for formulating final drug dosage forms. The excipients form the major part of any medicinal product and the proportion of it, when compared to Active Pharmaceutical Ingredient (API), exceeds two to three folds in any pharmaceutical preparations. Hence, various characteristics such as functionality, regulatory status, sources, cost, consistency, bioavailability, physicochemical properties, stability, pharmacokinetic parameters, etc. play a major role in determining the suitability of a substance as an excipient.

As estimated by IQ4I Research, the pharmaceutical excipients global market is expected to grow at mid single-digit CAGR from 2022 to 2029 to reach $15,439.6 million by 2029. The pharmaceutical excipients market is segmented based on source, products, functionality, and dosage forms.

The pharmaceutical excipients market based on the source is segmented as animal-based, plant-based, mineral-based, and synthetic-based excipients. Among them, plant-based excipients contributed the largest revenue in 2022 and it is the fastest growing segment at a high single digit CAGR from 2022 to 2029 due to plant-based excipients are cost-effective, low toxic with the better patient tolerance, bio-compatible and they are easily available. Based on products, excipients are segmented into inorganic chemicals, organic chemicals, and others. The organic chemical segment contributed the largest revenue in 2022 and it is expected to grow at mid single digit CAGR from 2022 to 2029 due to the use of these excipients in majorly all of the pharmaceutical formulations as they offer advantages such as increased efficacy in oral delivery of poorly soluble molecules along with increased compressibility and flowability properties.

The inorganic chemical excipients market based on product type is further divided into calcium salts, halites, metallic oxides, silicates, and other inorganic chemicals, among which metallic oxides contributed a major revenue in 2022 and the calcium salts segment is the fastest growing segment with a high single digit CAGR 2022 to 2029. Calcium salts are further sub-segmented into calcium phosphate, calcium carbonate, and others, among which, calcium phosphate contributed the largest revenue in 2022, and the calcium carbonate segment is expected to grow at a high single digit CAGR from 2022 to 2029. Calcium carbonate is further classified into GCC and PCC, among which PCC contributed the largest revenue in 2022 and it is expected to grow at a high single digit CAGR from 2022 to 2029. The metallic oxides segment is further segmented into titanium dioxide and others (Iron Oxide, Magnesium Oxide & Aluminum Hydroxide). Titanium Dioxide contributed the largest revenue in 2022 and it is expected to grow at mid single digit CAGR from 2022 to 2029.

The organic chemical excipients market by product type is further divided into carbohydrates, petrochemicals, oleochemicals, proteins, and other organic chemicals. Carbohydrates contributed major revenue in 2022 and it is expected to grow at mid single digit CAGR from 2022 to 2029.

The Carbohydrate excipients market based on product type is further segmented into sugar, starch, and cellulose, among which, cellulose contributed the largest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2029. The sugar segment is further divided into actual sugar, sugar alcohol, and artificial sweeteners, where actual sugar contributed the largest revenue in 2022 and the sugar alcohol segment is expected to grow at high single digit CAGR from 2022 to 2029.

The actual sugar segment is further sub-segmented into lactose, sucrose, and dextrose, where lactose contributed the largest revenue in 2022, and the sucrose segment is expected to grow at high single digit CAGR from 2022 to 2029. The sugar alcohol segment is further classified into sorbitol, mannitol, and other sugar alcohols, where mannitol contributed the largest revenue in 2022 and it is expected to grow at high single digit CAGR from 2022 to 2029. The starch segment is further divided into modified starch, dried starch, and converted starch, where modified starch contributed the largest revenue in 2022 and dried starch is expected to grow at mid single digit CAGR from 2022 to 2029. The cellulose segment is further sub-segmented into cellulose ethers, cellulose esters, croscarmellose sodium, and microcrystalline cellulose, where microcrystalline cellulose holds the largest revenue in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029.

The petrochemical excipients market based on product type is further segmented into glycols, povidones, mineral hydrocarbons, acrylic polymers, and other petrochemical excipients. Glycol contributed the largest revenue in 2022 and povidones are the fastest growing segment with a mid single digit CAGR from 2022 to 2029. The Glycol is further segmented into Polyethylene Glycol and Propylene Glycol, where Polyethylene Glycol contributed the largest revenue in 2022 and it is expected to grow at mid single digit CAGR from 2022 to 2029.

The Oleochemicals excipients market based on product type is further segmented into Fatty Alcohols, Mineral stearates, Glycerin, and Other Oleochemical Excipients. Fatty Alcohol contributed the largest revenue in 2022 and is expected to grow at mid single digit CAGR from 2022 to 2029 while mineral stearates is the fastest growing segment with mid single digit CAGR from 2022 to 2029.

Other excipients market based on product type is further segmented into the water for injections and purified water. Water for injections contributed the largest revenue in 2022 and it is expected to grow at low single digit CAGR from 2022 to 2029.

The pharmaceutical excipients market based on functionality is segmented as preservatives, solvents, binders & adhesives, fillers & diluents, suspending agents, coatings, solubilizers, disintegrants, colorants, flavoring & sweeteners, lubricants & glidants, and others. Binders & Adhesives contributed the largest revenue in 2022 and it is expected to grow at mid single digit CAGR from 2022 to 2029.

The pharmaceutical excipients market based on dosage forms is segmented as solid dosage forms, injectables and semisolids, and others. Solid dosage forms hold the largest revenue in 2022 and it is expected to grow at mid single digit CAGR from 2022 to 2029. Based on the manufacturing process solid dosage forms are segmented into granulation and direct compression. Granulation contributed the largest revenue in 2022 and direct compression is expected to grow at mid single digit CAGR from 2022 to 2029. Some of the factors driving the solid dosage forms market are cost-effectiveness, solid dosage provides increased physical and chemical stability, controlled-release options, and superior ease of handling.

The pharmaceutical excipients market based on region is segmented into North America (U.S. and the Rest of North America), Europe (Germany, France, Italy, and the Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of APAC) and Rest of the world (Brazil, Rest of Latin America and the Middle East & others). North America contributed the largest revenue in 2022 due to increasing demand for functional excipients, implementation of novelties like lipid nano particles, increasing usage of oral solid dosage forms, increasing incidence of chronic disorders, elderly population, and favorable reimbursement scenario for drugs. Also, technological innovations in the manufacturing procedures of excipients have propelled the market growth in North America. Stringent cGMP regulatory guidelines have resulted in a rising demand for high-grade excipients. In North America, the United States and Canada are the major markets observed due to its increasing investments in biopharmaceuticals, the growth in the demand for customized products, and advancements in multifunctional excipients in the market. Excipients manufacturers in developing countries face major challenges to develop a product with quality at an affordable price, due to the lower price of excipients and a large number of producers, which creates a price-sensitive market. Some manufacturers may compromise the quality of the product to keep prices low and boost sales, while some of the manufacturers having a larger market for their products, can sell their higher volume excipients at a slightly lower price. Asia-Pacific is the fastest-growing segment and is expected to grow at high single digit CAGR from 2022 to 2029.

Even though excipients are considered an essential component and have a major role in the drug delivery system, the lack of specific regulations, standardized tests, protocols, and guidelines is affecting the quality evaluation of excipients. Excipient manufacturers should follow WHO initiatives (GTDP, GMP), ICH Q3D, ICH Q1B, QBD requirements, PDG monograph harmonization, Good pharmacopeia practices, US FDA FDASIA, Title VII, E-DMF, and EU FMD. These regulations are compelling pharmaceutical manufacturers to develop a quality product by adopting various standard testing methods. EXCiPACT is a pharmaceutical excipients certification scheme to provide independent third-party certification of manufacturers, suppliers, and distributors of pharmaceutical excipients worldwide. EXiPACT certification enables to demonstrate that operations meet the minimum Good Manufacturing Practice (GMP) and/or Good Distribution Practice (GDP) requirements for excipients.

Presently, there is demand for the development of novel excipients with technological advancements like new chemical entity excipients, new chemically modified grade excipients, and existing excipients with the various route of administration and co-processed excipients. These novel excipients increase the scope for the development of new formulations and drug delivery systems which are a major gain for the industry, but the high cost and lengthy developmental process along with the safety and quality issues are delaying the excipients approval. Combinational excipients are mostly preferred by the manufacturers as the single excipients do not meet all the functional requirements such as high solubility, stability, and bioavailability.

The pharmaceutical excipients global market is highly competitive hence all the existing players in this market are involved in developing new and advanced therapeutics to maintain their market shares. Some of the key players contributing at the global level to pharmaceutical excipients market growth are IFF (U.S.), Ashland, Inc. (U.S.), BASF SE (Germany), DFE Pharma (Germany), Evonik Industries AG (Germany), Croda International Plc (U.K.), Merck KGAA (Germany), Roquette (France), Colorcon (U.S.), and Asahi Kasei (Japan).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • The U.S.
  • Rest of North America
  • Europe
  • Germany
  • France
  • Italy
  • Rest of Europe
  • Asia-Pacific 
  • China
  • India
  • Japan
  • Rest of APAC
  • Rest of the World (RoW)
  • Brazil
  • Rest of Latin America
  • The Middle East and Others
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DAT TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.5     PRIMARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     GROWTH IN GENERICS AND BIOSIMILAR DRUGS
        • 3.3.1.2     INCREASING DEMAND FOR ORAL SOLID DOSAGE FORM(OSDF) EXCIPIENTS
        • 3.3.1.3     INCREASING DEMAND FOR MULTIFUNCTIONAL EXCIPIENTS
        • 3.3.1.4     DRUG-COATED MEDICAL DEVICES
        • 3.3.1.5     INCREASING DEMAND FOR SOLUBILITY-ENHANCING EXCIPIENTS
        • 3.3.1.6     RISING DEMAND FOR SUSTAINED OR CONTROLLED-RELEASE FORMULATIONS
        • 3.3.1.7     INCREASING PREVALENCE OF CHRONIC DISEASES, RISE IN THE AGING POPULATION
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     ADVERSE REACTIONS OF EXCIPIENTS
        • 3.3.2.2     CONTAMINATION IN FORMULATIONS
        • 3.3.2.3     SUPPLY CHAIN ISSUES AND GEOPOLITICAL SCENARIOS IMPACTING THE MARKET
        • 3.3.2.4     CHALLENGES IN EXCIPIENTS INNOVATION
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     THE U.S.
      • 3.4.2     EUROPE
      • 3.4.3     JAPAN
      • 3.4.4     CHINA
      • 3.4.5     INDIA
      • 3.4.6     REST OF THE WORLD
      • 3.4.7     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
        • 3.4.7.1     ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM
      • 3.4.8     INTERNATIONAL PHARMACEUTICAL EXCIPIENTS COUNCIL (IPEC FEDERATION)
      • 3.4.9     PHARMACEUTICAL QUALITY GROUP (PQG)
      • 3.4.10     EXCIPACT-GMP/GDP CERTIFICATION
    • 3.5     PORTER'S FIVE FORCE ANALYSIS
      • 3.5.1     THREAT OF NEW ENTRANTS
      • 3.5.2     THREAT OF SUBSTITUTES
      • 3.5.3     BARGAINING POWER OF SUPPLIERS
      • 3.5.4     BARGAINING POWER OF BUYERS
      • 3.5.5     COMPETITIVE RIVALRY
    • 3.6     SUPPLY CHAIN ANALYSIS
    • 3.7     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.7.1     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE ANALYSIS
    • 3.8     NOVEL EXCIPIENTS
    • 3.9     POLYMER-BASED EXCIPIENTS
    • 3.10     LIPID-BASED EXCIPIENTS
    • 3.11     CARBOXYMETHYL CELLULOSE (CMC) PRODUCTION FROM LIGNOCELLULOSIC CORN AGRO-WASTE
    • 3.12     CONTAMINATION IN EXCIPIENTS
      • 3.12.1     (N-NITROSODIMETHYLAMINE)NDMA CONTAMINATION IN MEDICINES
      • 3.12.2     PHTHALATE EXCIPIENTS
    • 3.13     CHANGING LANDSCAPE OF THE EXCIPIENTS MARKET
    • 3.14     PHARMACEUTICAL EXCIPIENTS-FUNDING SCENARIO
    • 3.15     PHARMACEUTICAL EXCIPIENTS-ACQUISITION
    • 3.16     MOLECULE TYPE
    • 3.17     DRUG MASTER FILING (DMF)
    • 3.18     EXCIPIENTS BASED ON MOLECULE TYPE
    • 3.19     EXCIPIENTS PRICING
    • 3.20     GLOBAL PHARMACEUTICAL EXCIPIENTS PRODUCTION VOLUME
    • 3.21     EXCIPIENTS USED IN THE GLOBAL TOP 115 SELLING DRUGS BASED ON REVENUE
    • 3.22     EXCIPIENT MANUFACTURER'S REVENUE, PRODUCT, FUNCTIONALITY AND DOSAGE FORMS
  • 4     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BASED ON SOURCE
    • 4.1     INTRODUCTION
    • 4.2     ANIMAL-BASED EXCIPIENTS
    • 4.3     PLANT-BASED EXCIPIENTS
    • 4.4     MINERAL-BASED EXCIPIENTS
    • 4.5     SYNTHETIC-BASED EXCIPIENTS
  • 5     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BASED ON PRODUCT
    • 5.1     INTRODUCTION
    • 5.2     INORGANIC EXCIPIENTS
      • 5.2.1      CALCIUM SALT EXCIPIENTS
        • 5.2.1.1     CALCIUM PHOSPHATE EXCIPIENTS
        • 5.2.1.2     CALCIUM CARBONATE EXCIPIENTS
          • 5.2.1.2.1      GCC EXCIPIENTS
          • 5.2.1.2.2      PCC EXCIPIENTS
        • 5.2.1.3     OTHER CALCIUM SALT EXCIPIENTS
      • 5.2.2     HALITE EXCIPIENTS
      • 5.2.3     METALLIC OXIDE EXCIPIENTS
        • 5.2.3.1     TITANIUM DIOXIDE EXCIPIENTS
        • 5.2.3.2     OTHER METALLIC OXIDES EXCIPIENTS
      • 5.2.4     SILICATE EXCIPIENTS
      • 5.2.5     OTHER INORGANIC CHEMICAL EXCIPIENTS
    • 5.3     ORGANIC CHEMICAL EXCIPIENTS
      • 5.3.1     CARBOHYDRATE EXCIPIENTS
        • 5.3.1.1     SUGAR EXCIPIENTS
          • 5.3.1.1.1      ACTUAL SUGAR EXCIPIENTS
            • 5.3.1.1.1.1     LACTOSE EXCIPIENTS
            • 5.3.1.1.1.2     SUCROSE EXCIPIENTS
            • 5.3.1.1.1.3     DEXTROSE EXCIPIENTS
          • 5.3.1.1.2     SUGAR ALCOHOL EXCIPIENTS
            • 5.3.1.1.2.1     SORBITOL EXCIPIENTS
            • 5.3.1.1.2.2     MANNITOL EXCIPIENTS
            • 5.3.1.1.2.3     OTHER SUGAR ALCOHOLS EXCIPIENTS
          • 5.3.1.1.3     ARTIFICIAL SWEETENER EXCIPIENTS
        • 5.3.1.2     STARCH EXCIPIENTS
          • 5.3.1.2.1     MODIFIED STARCH EXCIPIENTS
          • 5.3.1.2.2     DRIED STARCH EXCIPIENTS
          • 5.3.1.2.3     CONVERTED STARCH EXCIPIENTS
        • 5.3.1.3     CELLULOSE EXCIPIENTS
          • 5.3.1.3.1     CELLULOSE ETHER EXCIPIENTS
          • 5.3.1.3.2     CELLULOSE ESTER EXCIPIENTS
          • 5.3.1.3.3     CROSCARMELLOSE SODIUM EXCIPIENTS
          • 5.3.1.3.4     MICROCRYSTALLINE CELLULOSE EXCIPIENTS
      • 5.3.2     PETROCHEMICAL EXCIPIENTS
        • 5.3.2.1     GLYCOL EXCIPIENTS
          • 5.3.2.1.1     POLYETHYLENE GLYCOL EXCIPIENTS
          • 5.3.2.1.2     PROPYLENE GLYCOL EXCIPIENTS
        • 5.3.2.2     POVIDONE EXCIPIENTS
        • 5.3.2.3     MINERAL HYDROCARBON EXCIPIENTS
        • 5.3.2.4     ACRYLIC POLYMER EXCIPIENTS
        • 5.3.2.5     OTHER PETROCHEMICAL EXCIPIENTS
      • 5.3.3     OLEOCHEMICAL EXCIPIENTS
        • 5.3.3.1     FATTY ALCOHOL EXCIPIENTS
        • 5.3.3.2     MINERAL STEARATE EXCIPIENTS
        • 5.3.3.3     GLYCERIN EXCIPIENTS
        • 5.3.3.4     OTHER OLEOCHEMICAL EXCIPIENTS
      • 5.3.4     PROTEIN EXCIPIENTS
      • 5.3.5     OTHER ORGANIC CHEMICAL EXCIPIENTS
    • 5.4     OTHER EXCIPIENTS
      • 5.4.1     WATER FOR INJECTION
      • 5.4.2     PURIFIED WATER EXCIPIENT
  • 6     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BASED ON FUNCTIONALITY
    • 6.1     INTRODUCTION
    • 6.2     PRESERVATIVE EXCIPIENTS
    • 6.3     SOLVENT EXCIPIENTS
    • 6.4     BINDER & ADHESIVE EXCIPIENTS
    • 6.5     FILLER & DILUENT EXCIPIENTS
    • 6.6     SUSPENDING AGENT EXCIPIENTS
    • 6.7     COATING EXCIPIENTS
    • 6.8     SOLUBILIZER EXCIPIENTS
    • 6.9     DISINTEGRANT EXCIPIENTS
    • 6.10     COLORANT, FLAVORING & SWEETENER EXCIPIENTS
    • 6.11     LUBRICANT & GLIDANT EXCIPIENTS
    • 6.12     OTHER EXCIPIENTS
  • 7     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BASED ON DOSAGE FORMS
    • 7.1     INTRODUCTION
    • 7.2     SOLID DOSAGE FORMS
      • 7.2.1     SOLID DOSAGE FORM GLOBAL MARKET, BASED ON MANUFACTURING PROCESS
        • 7.2.1.1     INTRODUCTION
        • 7.2.1.2     GRANULATION
        • 7.2.1.3     DIRECT COMPRESSION
    • 7.3     INJECTABLES
    • 7.4     SEMISOLIDS AND OTHER DOSAGE FORMS
  • 8     REGIONAL ANALYSIS
    • 8.1     INTRODUCTION
    • 8.2     NORTH AMERICA
      • 8.2.1     U.S.
      • 8.2.2     REST OF NORTH AMERICA
    • 8.3     EUROPE
      • 8.3.1     GERMANY
      • 8.3.2     FRANCE
      • 8.3.3     ITALY
      • 8.3.4     REST OF EUROPE
    • 8.4     APAC
      • 8.4.1     CHINA
      • 8.4.2     INDIA
      • 8.4.3     JAPAN
      • 8.4.4     REST OF APAC
    • 8.5     ROW
      • 8.5.1     BRAZIL
      • 8.5.2     REST OF LATAM
      • 8.5.3     MIDDLE EAST & OTHERS
  • 9     MAJOR COMPANIES
    • 9.1     ASHLAND, INC.
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     ASSOCIATED BRITISH FOODS, PLC (SPI PHARMA)
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     BASF SE
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     CRODA INTERNATIONAL, PLC
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     DOW CHEMICAL
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     DUPONT DE NEMOURS, INC
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     EVONIK INDUSTRIES, AG
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     FRIESLAND CAMPINA GERMANY GMBH(DFE PHARMA)
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     INTERNATIONAL FLAVORS & FRAGRANCES, INC.
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.10     KERRY GROUP
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 2     ESTIMATES OF THE PFIZER/BIONTECH (COMIRNATY) LIPID EXCIPIENTS REQUIRED (KG), AVERAGE SELLING PRICE (ASP) ($) AND REVENUE GENERATED ($MN) (2022)
      • TABLE 3     ESTIMATES OF THE MODERNA (SPIKEVAX) LIPID EXCIPIENTS REQUIRED (KG), AVERAGE SELLING PRICE (ASP) ($) AND REVENUE GENERATED ($MN) (2022)
      • TABLE 4     EXCIPIENTS PRICING
      • TABLE 5     GLOBAL PHARMACEUTICAL EXCIPIENTS REVENUE ($MN), AVERAGE SELLING PRICE ($/KG) AND PRODUCTION IN TONS, BASED ON PRODUCT (2022)
      • TABLE 6     GLOBAL PHARMACEUTICAL EXCIPIENTS PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)
      • TABLE 7     EXCIPIENTS USED IN GLOBAL TOP-SELLING DRUGS (2021)
      • TABLE 8     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON SOURCE, (2021-2029) ($MN)
      • TABLE 9     ANIMAL-BASED EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 10     PLANT-BASED EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 11     MINERAL-BASED EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 12     SYNTHETIC-BASED EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 13     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 14     PHARMACEUTICAL EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)
      • TABLE 15     INORGANIC EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)
      • TABLE 16     INORGANIC EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 17     INORGANIC EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 18     CALCIUM SALT EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)
      • TABLE 19     CALCIUM SALT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 20     CALCIUM SALT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 21     CALCIUM PHOSPHATE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 22     CALCIUM CARBONATE EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)
      • TABLE 23     CALCIUM CARBONATE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 24     CALCIUM CARBONATE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 25     GCC EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 26     PCC EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 27     OTHER CALCIUM SALT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 28     HALITE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 29     METALLIC OXIDE EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)
      • TABLE 30     METALLIC OXIDE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 31     METALLIC OXIDE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 32     TITANIUM DIOXIDE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 33     OTHER METALLIC OXIDE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 34     SILICATE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 35     OTHER INORGANIC CHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 36     ORGANIC CHEMICAL EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT TYPE, (2021-2029) (TONS)
      • TABLE 37     ORGANIC CHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 38     ORGANIC CHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 39     CARBOHYDRATE EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)
      • TABLE 40     CARBOHYDRATE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 41     CARBOHYDRATE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 42     SUGAR EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)
      • TABLE 43     SUGAR EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 44     SUGAR EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 45     ACTUAL SUGAR EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 46     ACTUAL SUGAR EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 47     LACTOSE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 48     SUCROSE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 49     DEXTROSE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 50     SUGAR ALCOHOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 51     SUGAR ALCOHOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 52     SORBITOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 53     MANNITOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 54     OTHER SUGAR ALCOHOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 55     ARTIFICIAL SWEETENER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 56     STARCH EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)
      • TABLE 57     STARCH EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 58     STARCH EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 59     MODIFIED STARCH EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 60     DRIED STARCH EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 61     CONVERTED STARCH EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 62     CELLULOSE EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)
      • TABLE 63     CELLULOSE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 64     CELLULOSE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 65     CELLULOSE ETHER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 66     CELLULOSE ESTER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 67     CROSCARMELLOSE SODIUM EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 68     MICROCRYSTALLINE CELLULOSE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 69     PETROCHEMICAL EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)
      • TABLE 70     PETROCHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 71     PETROCHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 72     GLYCOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 73     GLYCOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 74     POLYETHYLENE GLYCOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 75     PROPYLENE GLYCOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 76     POVIDONE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 77     MINERAL HYDROCARBON EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 78     ACRYLIC POLYMER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 79     OTHER PETROCHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 80     OLEOCHEMICAL EXCIPIENTS GLOBAL PRODUCTION, BASED ON PRODUCT, (2021-2029) (TONS)
      • TABLE 81     OLEOCHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 82     OLEOCHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 83     FATTY ALCOHOL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 84     MINERAL STEARATE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 85     GLYCERIN EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 86     OTHER OLEOCHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 87     PROTEIN EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 88     OTHER ORGANIC CHEMICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 89     OTHER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 90     OTHER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 91     WATER FOR INJECTION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 92     PURIFIED WATER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 93     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON FUNCTIONALITY, (2021-2029) ($MN)
      • TABLE 94     PRESERVATIVE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 95     SOLVENT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 96     BINDER & ADHESIVE EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 97     FILLER & DILUENT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 98     SUSPENDING AGENT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 99     COATING EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 100     SOLUBILIZER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 101     DISINTEGRANT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 102     COLORANT, FLAVORING & SWEETENER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 103     LUBRICANT & GLIDANT EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 104     OTHER EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 105     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON DOSAGE FORMS, (2021-2029) ($MN)
      • TABLE 106     SOLID DOSAGE FORMS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 107     SOLID DOSAGE FORM GLOBAL MARKET, BASED ON MANUFACTURING PROCESS, (2021-2029) ($MN)
      • TABLE 108     GRANULATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 109     DIRECT COMPRESSION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 110     INJECTABLES DOSAGE FORM GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 111     INJECTABLES DOSAGE FORM GLOBAL MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2021-2029) ($MN)
      • TABLE 112     SEMISOLIDS AND OTHER DOSAGE FORMS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 113     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 114     NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE, (2021-2029) ($MN)
      • TABLE 115     NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 116     NORTH AMERICAN INORGANIC EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 117     NORTH AMERICAN CALCIUM SALT EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 118     NORTH AMERICAN CALCIUM CARBONATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 119     NORTH AMERICAN METALLIC OXIDES EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 120     NORTH AMERICAN ORGANIC EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 121     NORTH AMERICAN CARBOHYDRATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 122     NORTH AMERICAN SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 123     NORTH AMERICAN ACTUAL SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 124     NORTH AMERICAN SUGAR ALCOHOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 125     NORTH AMERICAN STARCH EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 126     NORTH AMERICAN CELLULOSE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 127     NORTH AMERICAN PETROCHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 128     NORTH AMERICAN GLYCOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 129     NORTH AMERICAN OLEOCHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 130     NORTH AMERICAN OTHER EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 131     NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY, (2021-2029) ($MN)
      • TABLE 132     NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS, (2021-2029) ($MN)
      • TABLE 133     NORTH AMERICAN SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS, (2021-2029) ($MN)
      • TABLE 134     NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 135     EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE, (2021-2029) ($MN)
      • TABLE 136     EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 137     EUROPEAN INORGANIC CHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 138     EUROPEAN CALCIUM SALT EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 139     EUROPEAN CALCIUM CARBONATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 140     EUROPEAN METALLIC OXIDES EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 141     EUROPEAN ORGANIC EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 142     EUROPEAN CARBOHYDRATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 143     EUROPEAN SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 144     EUROPEAN ACTUAL SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 145     EUROPEAN SUGAR ALCOHOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 146     EUROPEAN STARCH EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 147     EUROPEAN CELLULOSE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 148     EUROPEAN PETROCHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 149     EUROPEAN GLYCOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 150     EUROPEAN OLEOCHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 151     EUROPEAN OTHER EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 152     EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY, (2021-2029) ($MN)
      • TABLE 153     EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS, (2021-2029) ($MN)
      • TABLE 154     EUROPEAN SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS, (2021-2029) ($MN)
      • TABLE 155     EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 156     APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE, (2021-2029) ($MN)
      • TABLE 157     APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 158     APAC INORGANIC CHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 159     APAC CALCIUM SALT EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 160     APAC CALCIUM CARBONATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 161     APAC METALLIC OXIDES EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 162     APAC ORGANIC CHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 163     APAC CARBOHYDRATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 164     APAC SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 165     APAC ACTUAL SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 166     APAC SUGAR ALCOHOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 167     APAC STARCH EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 168     APAC CELLULOSE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 169     APAC PETROCHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 170     APAC GLYCOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 171     APAC OLEOCHEMICALS EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 172     APAC OTHER EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 173     APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY, (2021-2029) ($MN)
      • TABLE 174     APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS, (2021-2029) ($MN)
      • TABLE 175     APAC SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS, (2021-2029) ($MN)
      • TABLE 176     APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 177     ROW PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE, (2021-2029) ($MN)
      • TABLE 178     ROW PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 179     ROW INORGANIC EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 180     ROW CALCIUM SALT EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 181     ROW CALCIUM CARBONATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 182     ROW METALLIC OXIDES EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 183     ROW ORGANIC CHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 184     ROW CARBOHYDRATE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN)
      • TABLE 185     ROW SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 186     ROW ACTUAL SUGAR EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 187     ROW SUGAR ALCOHOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 188     ROW STARCH EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 189     ROW CELLULOSE EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 190     ROW PETROCHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 191     ROW GLYCOL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 192     ROW OLEOCHEMICAL EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 193     ROW OTHER EXCIPIENTS MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 194     ROW PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY, (2021-2029) ($MN)
      • TABLE 195     ROW PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS, (2021-2029) ($MN)
      • TABLE 196     ROW SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS, (2021-2029) ($MN)
      • TABLE 197     ROW PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 198     ASHLAND, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) ($MN)
      • TABLE 199     ASHLAND, INC.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022) ($MN)
      • TABLE 200     ASHLAND, INC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) ($MN)
      • TABLE 201     ASHLAND, INC.: LIFE SCIENCE GEOGRAPHY REVENUE, (2020-2022) ($MN)
      • TABLE 202     ASSOCIATED BRITISH FOODS, PLC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) ($MN)
      • TABLE 203     ASSOCIATED BRITISH FOODS, PLC: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022) ($MN)
      • TABLE 204     ASSOCIATED BRITISH FOODS, PLC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) ($MN)
      • TABLE 205     BASF SE: TOTAL REVENUE AND R&D EXPENSES, (2020-2022(Q2)) ($MN)
      • TABLE 206     BASF SE: TOTAL REVENUE, BY SEGMENT, (2020-2022(Q2)) ($MN)
      • TABLE 207     BASF SE: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022(Q2)) ($MN)
      • TABLE 208     CRODA INTERNATIONAL, PLC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022(Q2)) ($MN)
      • TABLE 209     CRODA INTERNATIONAL, PLC: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022(Q2)) ($MN)
      • TABLE 210     CRODA INTERNATIONAL, PLC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q2)) ($MN)
      • TABLE 211     DOW CHEMICAL: TOTAL REVENUE AND R&D EXPENSES, (2020-2022(Q3)) ($MN)
      • TABLE 212     DOW CHEMICAL: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022(Q3)) ($MN)
      • TABLE 213     DOW CHEMICAL: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q3)) ($MN)
      • TABLE 214     DUPONT DE NEMOURS, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022(Q3)) ($MN)
      • TABLE 215     DUPONT DE NEMOURS, INC: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022(Q3)) ($MN)
      • TABLE 216     DUPONT DE NEMOURS, INC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q3)) ($MN)
      • TABLE 217     EVONIK INDUSTRIES, AG: TOTAL REVENUE AND R&D EXPENSES, (2020-2022(Q3)) ($MN)
      • TABLE 218     EVONIK INDUSTRIES, AG: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022(Q3)) ($MN)
      • TABLE 219     EVONIK INDUSTRIES, AG: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q3)) ($MN)
      • TABLE 220     FRIESLAND CAMPINA GERMANY GMBH (DFE PHARMA): TOTAL REVENUE AND R&D EXPENSES, (2020-2022(Q2)) ($MN)
      • TABLE 221     FRIESLAND CAMPINA GERMANY GMBH (DFE PHARMA): TOTAL REVENUE, BASED ON SEGMENT, (2020-2022(Q2)) ($MN)
      • TABLE 222     FRIESLAND CAMPINA GERMANY GMBH (DFE PHARMA): TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q2)) ($MN)
      • TABLE 223     IFF, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022(Q2)) ($MN)
      • TABLE 224     IFF, INC: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022(Q2)) ($MN)
      • TABLE 225     IFF, INC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q2)) ($MN)
      • TABLE 226     KERRY GROUP: TOTAL REVENUE AND R&D EXPENSES, (2020-2022(Q2)) ($MN)
      • TABLE 227     KERRY GROUP: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022(Q2)) ($MN)
      • TABLE 228     KERRY GROUP: TOTAL REVENUE, BASED ON SUB-SEGMENT, (2020-2022(Q2)) ($MN)
      • TABLE 229     KERRY GROUP: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q2)) ($MN)

      LIST OF FIGURES

      • FIGURE 1     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET
      • FIGURE 3     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SEGMENTATION
      • FIGURE 7     INORGANIC CHEMICAL EXCIPIENTS GLOBAL MARKET SEGMENTATION
      • FIGURE 8     ORGANIC CHEMICAL EXCIPIENTS GLOBAL MARKET SEGMENTATION
      • FIGURE 9     MARKET DYNAMICS
      • FIGURE 10     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET: PORTER'S ANALYSIS
      • FIGURE 11     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 12     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 13     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET, BASED ON MOLECULE TYPE, 2022 (%)
      • FIGURE 14     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON SOURCE (2022 V/S 2029) (%)
      • FIGURE 15     PLANT-BASED EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 16     MINERAL-BASED EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 17     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 18     INORGANIC EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 19     INORGANIC EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 20     CALCIUM SALT EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 21     CALCIUM SALT EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 22     CALCIUM CARBONATE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 23     GCC EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 24     PCC EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 25     OTHER CALCIUM SALT EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 26     METALLIC OXIDE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 27     METALLIC OXIDE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 28     TITANIUM DIOXIDE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 29     OTHER METALLIC OXIDE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 30     SILICATE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 31     ORGANIC CHEMICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 32     CARBOHYDRATE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 33     CARBOHYDRATE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 34     SUGAR EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 35     SUGAR EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 36     ACTUAL SUGAR EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 37     ACTUAL SUGAR EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 38     LACTOSE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 39     SUCROSE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 40     SUGAR ALCOHOL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 41     STARCH EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 42     MODIFIED STARCH EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 43     DRIED STARCH EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 44     CONVERTED STARCH EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 45     CELLULOSE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 46     CELLULOSE ETHER EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 47     CELLULOSE ESTER EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 48     CROSCARMELLOSE SODIUM EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 49     MICROCRYSTALLINE CELLULOSE EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 50     PETROCHEMICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 51     GLYCOL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 52     OLEOCHEMICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 53     OTHER EXCIPIENTS GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 54     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON FUNCTIONALITY (2022 V/S 2029) (%)
      • FIGURE 55     SOLVENT EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 56     COLORANT, FLAVORING & SWEETENER EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 57     LUBRICANT & GLIDANT EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 58     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON DOSAGE FORMS (2022 V/S 2029) (%)
      • FIGURE 59     SOLID DOSAGE FORM GLOBAL MARKET SHARE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) (%)
      • FIGURE 60     GRANULATION GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 61     INJECTABLES DOSAGE FORM GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
      • FIGURE 62     INJECTABLES DOSAGE FORM GLOBAL MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION, (2022 V/S 2029) (%)
      • FIGURE 63     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN), CAGR (%)
      • FIGURE 64     PHARMACEUTICAL EXCIPIENTS GLOBAL MARKET SHARE, BASED ON REGION, REVENUE BASED ON COUNTRY (2022) (%)($MN)
      • FIGURE 65     NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON SOURCE (2022 V/S 2029) (%)
      • FIGURE 66     NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 67     NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON FUNCTIONALITY (2022 VS 2029) (%)
      • FIGURE 68     NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON DOSAGE FORMS (2022 V/S 2029) (%)
      • FIGURE 69     NORTH AMERICAN PHARMACEUTICAL EXCIPIENTS SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 70     U.S. PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCTS (2022 V/S 2029) ($MN)
      • FIGURE 71     U.S. PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) ($MN)
      • FIGURE 72     U.S. SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) ($MN)
      • FIGURE 73     U.S. PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) ($MN)
      • FIGURE 74     REST OF NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCTS (2022 V/S 2029) ($MN)
      • FIGURE 75     REST OF NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE BASED ON DOSAGE FORMS (2022 V/S 2029) ($MN)
      • FIGURE 76     REST OF NORTH AMERICA SOLID DOSAGE FORMS MARKET REVENUE BASED ON MANUFACTURING PROCESS (2022 V/S 2029) ($MN)
      • FIGURE 77     REST OF NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) ($MN)
      • FIGURE 78     EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON SOURCE (2022 V/S 2029) (%)
      • FIGURE 79     EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 80     EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON FUNCTIONALITY (2022 VS 2029) (%)
      • FIGURE 81     EUROPEAN PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON DOSAGE FORMS (2022) (%), CAGR (%)
      • FIGURE 82     EUROPEAN PHARMACEUTICAL EXCIPIENTS SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 83     GERMANY PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCTS (2022 V/S 2029) ($MN)
      • FIGURE 84     GERMANY PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) ($MN)
      • FIGURE 85     GERMANY SOLID DOSAGE FORM MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) ($MN)
      • FIGURE 86     GERMANY PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) ($MN)
      • FIGURE 87     FRANCE PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCT (2022 V/S 2029) ($MN)
      • FIGURE 88     FRANCE PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) ($MN)
      • FIGURE 89     FRANCE SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) ($MN)
      • FIGURE 90     FRANCE PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) ($MN)
      • FIGURE 91     ITALY PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCT (2022 V/S 2029) ($MN)
      • FIGURE 92     ITALY PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) ($MN)
      • FIGURE 93     ITALY SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) ($MN)
      • FIGURE 94     ITALY PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) ($MN)
      • FIGURE 95     REST OF EUROPE PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCT (2022 V/S 2029) ($MN)
      • FIGURE 96     REST OF EUROPE PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) ($MN)
      • FIGURE 97     REST OF EUROPE SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) ($MN)
      • FIGURE 98     REST OF EUROPE PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) ($MN)
      • FIGURE 99     APAC PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON SOURCE (2022 V/S 2029) (%)
      • FIGURE 100     APAC PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 101     APAC PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON FUNCTIONALITY (2022 V/S 2029) (%)
      • FIGURE 102     APAC PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON DOSAGE FORMS (2022 V/S 2029) (%)
      • FIGURE 103     APAC PHARMACEUTICAL EXCIPIENTS SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 104     CHINA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCTS (2022 V/S 2029) ($MN)
      • FIGURE 105     CHINA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) ($MN)
      • FIGURE 106     CHINA SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) ($MN)
      • FIGURE 107     CHINA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) ($MN)
      • FIGURE 108     INDIA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCTS (2022 V/S 2029) ($MN)
      • FIGURE 109     INDIA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) ($MN)
      • FIGURE 110     INDIA SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) ($MN)
      • FIGURE 111     INDIA PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022) ($MN), CAGR (%)
      • FIGURE 112     JAPAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCT (2022 V/S 2029) ($MN)
      • FIGURE 113     JAPAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) ($MN)
      • FIGURE 114     JAPAN SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) ($MN)
      • FIGURE 115     JAPAN PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) ($MN)
      • FIGURE 116     REST OF APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCTS (2022 V/S 2029) ($MN)
      • FIGURE 117     REST OF APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) ($MN)
      • FIGURE 118     REST OF APAC SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) ($MN)
      • FIGURE 119     REST OF APAC PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) ($MN)
      • FIGURE 120     ROW PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON SOURCE (2022 VS 2029) (%)
      • FIGURE 121     ROW PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON PRODUCT (2022 VS 2029) (%)
      • FIGURE 122     ROW PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON FUNCTIONALITY (2022 VS 2029) (%)
      • FIGURE 123     ROW PHARMACEUTICAL EXCIPIENTS MARKET SHARE, BASED ON DOSAGE FORMS (2022 V/S 2029) (%)
      • FIGURE 124     ROW PHARMACEUTICAL EXCIPIENTS SHARE, BASED ON COUNTRY, (2022 V/S 2029) (%)
      • FIGURE 125     BRAZIL PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCT (2022 V/S 2029) ($MN)
      • FIGURE 126     BRAZIL PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) ($MN)
      • FIGURE 127     BRAZIL SOLID DOSAGE MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) ($MN)
      • FIGURE 128     BRAZIL PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) ($MN)
      • FIGURE 129     REST OF LATAM PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCT (2022 V/S 2029) ($MN)
      • FIGURE 130     REST OF LATAM PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) ($MN)
      • FIGURE 131     REST OF LATAM SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) ($MN)
      • FIGURE 132     REST OF LATAM PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) ($MN)
      • FIGURE 133     MIDDLE EAST & OTHERS PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON SOURCE AND PRODUCT (2022 V/S 2029) ($MN)
      • FIGURE 134     MIDDLE EAST & OTHERS PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON DOSAGE FORMS (2022 V/S 2029) ($MN)
      • FIGURE 135     MIDDLE EAST & OTHERS SOLID DOSAGE FORMS MARKET REVENUE, BASED ON MANUFACTURING PROCESS (2022 V/S 2029) ($MN)
      • FIGURE 136     MIDDLE EAST & OTHERS PHARMACEUTICAL EXCIPIENTS MARKET REVENUE, BASED ON FUNCTIONALITY (2022 VS 2029) ($MN)
      • FIGURE 137     SWOT: ASHLAND, INC.
      • FIGURE 138     SWOT: ASSOCIATED BRITISH FOODS, PLC (SPI PHARMA)
      • FIGURE 139     SWOT: BASF SE
      • FIGURE 140     SWOT: CRODA INTERNATIONAL, PLC.
      • FIGURE 141     SWOT: DOW CHEMICAL
      • FIGURE 142     SWOT: DUPONT DE NEMOURS, INC.
      • FIGURE 143     SWOT: EVONIK INDUSTRIES, AG
      • FIGURE 144     SWOT: FRIESLAND CAMPINA
      • FIGURE 145     SWOT: INTERNATIONAL FLAVORS & FRAGRANCES, INC. (IFF)
      • FIGURE 146     SWOT: KERRY GROUP

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     2M holding (U.K.)
      • 2     AAK (Sweden)
      • 3     Aastrid International (India)
      • 4     Accent Microcell Private Limited (India)
      • 5     Aceto Corporation (U.S.)
      • 6     ACG Associated Capsules Private Limited (India)
      • 7     Acme-Hardesty (U.S.)
      • 8     Advance Scientific & Chemical Inc (U.S.)
      • 9     AerChem Inc (U.S.)
      • 10     Akhil Healthcare Pvt. Ltd. (India)
      • 11     Akzo Nobel (The Netherlands)
      • 12     Allan Chemical Corp (U.S.)
      • 13     Alland & Robert (France)
      • 14     Allchem Pharma Ingredients (U.K.)
      • 15     Alzo International Inc (U.S.)
      • 16     American International Chemical Inc (U.S.)
      • 17     American Lecithin Co (U.S.)
      • 18     Anhui Sunhere Pharmaceutical Excipients Co., Ltd. (China)
      • 19     AnMar International (tc) (U.S.)
      • 20     Archer Daniels Midland Company (U.S.)
      • 21     Arihant Innochem PVT LTD (India)
      • 22     Armor Pharma (France)
      • 23     Asahi Kasei Corporation (Japan)
      • 24     Asha Cellulose (I) Pvt. Ltd. (India)
      • 25     Ashland Inc (U.S.)
      • 26     Asiamerica Ingredients Inc (U.S.)
      • 27     Associated British Foods Plc (U.K.)
      • 28     Astro Chemicals Inc (U.S.)
      • 29     Aug. Hedinger GmbH & Co. KG (Germany)
      • 30     Avantor, Inc. (U.S.)
      • 31     Avatar Corporation (U.S.)
      • 32     Avonchem Ltd (U.K.)
      • 33     Azelis (Belgium)
      • 34     Barrington Nutritionals (U.S.)
      • 35     BASF SE (Germany)
      • 36     BDI Pharma Inc (U.S.)
      • 37     Beneo Gmbh (Germany)
      • 38     Berg + Schmidt GmbH & Co. KG (Germany)
      • 39     Biddle Sawyer Corporation (U.S.)
      • 40     Biesterfeld Spezialchemie GmbH (Germany)
      • 41     Bio Products Laboratory (U.K.)
      • 42     Biogel AG (Switzerland)
      • 43     Biogrund GmbH (Germany)
      • 44     Blagden Specialty Chemicals Ltd (U.K.)
      • 45     Blanver (Brazil)
      • 46     BOC Sciences (U.S.)
      • 47     Borax Europe Ltd (U.K.)
      • 48     BP Inc (U.K.)
      • 49     Budenheim USA Inc (U.S.)
      • 50     CarboMer Inc (U.S.)
      • 51     Cargill Corporation (U.S.)
      • 52     Celanese Corporation (U.S.)
      • 53     Charles B Chrystal Co Inc (U.S.)
      • 54     Chemfield Cellulose Pvt. Ltd. (India)
      • 55     Chemical Inc (U.S.)
      • 56     Chemische Fabrik Budenheim KG (Germany)
      • 57     Chempilots a/s (Denmark)
      • 58     Chemtura Corporation (U.S.)
      • 59     Colorcon Inc. (U.S.)
      • 60     Corcoran Chemicals Ltd (Ireland)
      • 61     CordenPharma International (Germany)
      • 62     Corel Pharma Chem (India)
      • 63     Cornelius Group pic (U.K.)
      • 64     CP Kelco US Inc (U.S.)
      • 65     CPI Chemicals (Austria)
      • 66     Crest Cellulose Pvt. Ltd. (India)
      • 67     Croda International Plc (U.K.)
      • 68     CSL Behring (U.S.)
      • 69     CSPC Pharma (China)
      • 70     CyDex Pharmaceuticals, Inc. (U.S.)
      • 71     Daffodil Pharma (India)
      • 72     Dastech International Inc (U.S.)
      • 73     Dow Chemical corporation (U.S.)
      • 74     Dr Paul Lohmann GmbH KG (Germany)
      • 75     Dupont De Nemours, Inc. (U.S.)
      • 76     Eastman Chemical Company (U.S.)
      • 77     ESSECO UK Ltd (U.K.)
      • 78     Evonik Industries AG (Germany)
      • 79     Ferro Corporation (U.S.)
      • 80     Fitzgerald Industries International (U.S.)
      • 81     Friesland Campina Germany GmbH (Germany)
      • 82     Gadot Petrochemical Industries Ltd (Israel)
      • 83     Gangwal Chemicals Private Limited (India)
      • 84     Gattefosse Corporation (U.S.)
      • 85     Gelnex (Brazil)
      • 86     Geltech Co Ltd (South Korea)
      • 87     Generichem Corporation (U.S.)
      • 88     George Uhe Co Inc (U.S.)
      • 89     GFS Chemicals Inc (U.S.)
      • 90     Gifu Shellac Co Ltd (Japan)
      • 91     Glide Chem Pvt Ltd (India)
      • 92     Grifols LLC (U.S.)
      • 93     Hawkins Inc (U.S.)
      • 94     HBCChem Inc (U.S.)
      • 95     Helm AG (Germany)
      • 96     Hengyang Desen Biotechnology Co., Ltd. (China)
      • 97     Horsehead Corporation (U.S.)
      • 98     Hummel Croton Inc (U.S.)
      • 99     Huzhou Zhanwang Pharmaceutical Co., Ltd. (China)
      • 100     Ideal Cures Pvt. Ltd. (India)
      • 101     IEQSA (Peru)
      • 102     IMCD Group BV (The Netherlands)
      • 103     IMPAG Group (Germany)
      • 104     Imperial-Oel-Import (Germany)
      • 105     Ingredion Incorporated (U.S.)
      • 106     Innophos Inc (U.S.)
      • 107     Integra Chemical Co (U.S.)
      • 108     Intermag Co Ltd (U.K.)
      • 109     James M Brown Ltd (U.K.)
      • 110     Jaysons API Private Limited (India)
      • 111     JD Pharmasciences (India)
      • 112     JRS pharma (Germany)
      • 113     Junca Gelatines SL (Spain)
      • 114     Jungbunzlauer AG (Switzerland)
      • 115     Kao Corporation (Japan)
      • 116     Kasyap Sweetners Limited (India)
      • 117     Kerry Group (Ireland)
      • 118     KIC Chemicals Inc (U.S.)
      • 119     Kraft Chemical Co (U.S.)
      • 120     Kronos Ltd (U.S.)
      • 121     Lactose India Ltd. (India)
      • 122     Lapi Gelatine SpA (Italy)
      • 123     Lehmann & Voss & Co (Germany)
      • 124     Liaoning Oxiranphex Inc. (China)
      • 125     Lipo Chemicals Inc (U.S.)
      • 126     Lonza Group (Switzerland)
      • 127     Lubrizol Corporation (U.S.)
      • 128     Lucid Colloids Ltd (India)
      • 129     Lyondell Chemical Co (The Netherlands)
      • 130     Magnesia GmbH (Germany)
      • 131     Mantrose Ltd (U.S.)
      • 132     Maple Biotech Private Limited (India)
      • 133     Meggle Group (Germany)
      • 134     Merck EMD (U.S.)
      • 135     Merck KGaA (Germany)
      • 136     Microchem srl (Italy)
      • 137     Mineral Technologies Inc. (U.S.)
      • 138     Napp Technologies LLC (U.S.)
      • 139     NB Entrepreneurs (India)
      • 140     Nippi Inc (Japan)
      • 141     Nippon Soda Co Ltd (Japan)
      • 142     Nitika Pharmaceuticals Specialities Pvt. Ltd. (India)
      • 143     Nitta Gelatin Inc (Japan)
      • 144     NP Pharm (India)
      • 145     Omya International AG (Switzerland)
      • 146     Panreac Quimica SAU (Illinois Tool Works) (U.S.)
      • 147     Parc hem (U.S.)
      • 148     Patel Chem Specialities Private Limited (India)
      • 149     Paushak Limited (India)
      • 150     PB Leiner (U.S.)
      • 151     Penta Manufacturing Co (U.S.)
      • 152     Perrigo Company PLC (Ireland)
      • 153     Peter Whiting (Chemicals) Ltd (U.K.)
      • 154     Pfanstiehl Inc. (U.S.)
      • 155     Pharmatrans Sanaq AG (Switzerland)
      • 156     Polysciences Inc (U.S.)
      • 157     Premium Ingredients Ltd (Spain)
      • 158     Priyanka Pharma/M K Ingredients ÔC Specialities (India)
      • 159     Protameen Chemicals Inc (U.S.)
      • 160     Raught Ltd (U.K.)
      • 161     Reheis (U.S.)
      • 162     Reinert Gruppe GmbH ÔC Co KG (Germany)
      • 163     Reliance Cellulose Products Limited (India)
      • 164     Rettenmaier Ltd (U.K.)
      • 165     Rhodia Inc (France)
      • 166     RIA International (U.S.)
      • 167     Roche Products Ltd (U.K.)
      • 168     Roquette Frères SA (France)
      • 169     Rousselot Inc (U.S.)
      • 170     RT Vanderbilt Company Inc (U.S.)
      • 171     Rubamin Ltd (India)
      • 172     RW Unwin & Co Ltd (U.K.)
      • 173     Sachtleben Chemie GmbH (Germany)
      • 174     Sasol (South Africa)
      • 175     Saudi Kayan Petrochemical Company (SABIC) (Saudi Arabia)
      • 176     Savvy Spechems Private Limited (India)
      • 177     SD Fine-Chem Ltd (India)
      • 178     SE Tylose GmbH Co.KG (Germany)
      • 179     Select chemie AG (Switzerland)
      • 180     Sensient Technologies (U.S.)
      • 181     Seppic SA (France)
      • 182     Seqens SAS (France)
      • 183     SGS Italia S.p.A (Italy)
      • 184     Sheffield Bio-Science (U.S.)
      • 185     Shin-Etsu Chemical Co Ltd (Japan)
      • 186     Shreeji Pharma International (India)
      • 187     Sigachi Industries Private Limited (India)
      • 188     SNA Healthcare Private Limited (India)
      • 189     Solvay SA (Belgium)
      • 190     Spectrum Chemical Manufacturing Corp. (U.S.)
      • 191     Stearinerie Dubois (France)
      • 192     Stroever GmbH & Co. KG (Germany)
      • 193     Sudeep Pharma Pvt. Ltd. (India)
      • 194     Surfachem Group Ltd. (U.K.)
      • 195     Tata Chemicals (India)
      • 196     Tereos SA (France)
      • 197     The Rousselot Gelatin Co Ltd (China)
      • 198     Thew, Arnott and Co Ltd (U.K.)
      • 199     Tioxide Americas Inc (U.S.)
      • 200     Valtris Specialty Chemical (U.S.)
      • 201     Venator Materials PLC (U.K.)
      • 202     Vikaash Chemicals (India)
      • 203     Vikram Thermo Ltd. (India)
      • 204     W. R. Grace & Co.-Conn. (U.S.)
      • 205     Wacker Chemie AG (Germany)
      • 206     Weishardt International, Canada (France)
      • 207     Whittaker Clark, and Daniels Inc (U.S.)
      • 208     William Ransom Son pic (U.K.)
      • 209     Wintersun Chemical (U.S.)
      • 210     Xiamen ShengLang SaiChuang Biological Technology Co. (China)
      • 211     Xinchem Co (China)
      • 212     Zhonghua Fangda (HK) Ltd (China)
      • 213     Zuchem Inc. (U.S.)